MARKET

GLYC

GLYC

GlycoMimetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.550
+0.120
+4.94%
After Hours: 2.680 +0.13 +5.10% 19:58 05/18 EDT
OPEN
2.460
PREV CLOSE
2.430
HIGH
2.660
LOW
2.430
VOLUME
667.03K
TURNOVER
--
52 WEEK HIGH
5.19
52 WEEK LOW
2.110
MARKET CAP
131.42M
P/E (TTM)
-2.0969
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Benzinga · 5d ago
GlycoMimetics, Ocuphire Pharma Shares Tick Higher; Trader Circulate Article Titled '2 "Strong Buy" Penny Stocks That Could See Outsized Gains'
https://www.tipranks.com/news/article/2-strong-buy-penny-stocks-that-could-see-outsized-gains-2/
Benzinga · 5d ago
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11)
Benzinga · 6d ago
GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Might Not Expect Shareholders To Be So Generous This Year
GlycoMimetics, Inc. ( NASDAQ:GLYC ) has not performed well recently and CEO Rachel King will probably need to up their...
Simply Wall St. · 6d ago
3 Net Current Asset Value Stock Picks
GuruFocus News · 05/11 15:59
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10)
Benzinga · 05/11 11:54
Stocks That Hit 52-Week Lows On Monday
  Monday morning saw 78 companies set new 52-week lows.
Benzinga · 05/10 14:41
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6)
Benzinga · 05/07 11:40
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GLYC. Analyze the recent business situations of GlycoMimetics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GLYC stock price target is 10.67 with a high estimate of 15.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 138
Institutional Holdings: 51.46M
% Owned: 99.85%
Shares Outstanding: 51.54M
TypeInstitutionsShares
Increased
26
2.49M
New
7
737.25K
Decreased
25
1.20M
Sold Out
18
4.05M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.42%
Pharmaceuticals & Medical Research
+0.07%
Key Executives
Non-Executive Chairman/Independent Director
Timothy Pearson
President/Chief Executive Officer/Co-Founder/Director
Rachel King
Co-Founder/Senior Vice President/Chief Scientific Officer
John Magnani
Chief Financial Officer/Senior Vice President
Brian Hahn
Senior Vice President
Eric Feldman
Senior Vice President
Armand Girard
Independent Director
Patricia Andrews
Independent Director
Mark Goldberg
Independent Director
Scott Jackson
Independent Director
Daniel Junius
Independent Director
Scott Koenig
No Data
About GLYC
GlycoMimetics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. Its drug candidates include Uproleselan, GMI-1687, GMI-1359, Galectin Antagonists and Rivipansel. Uproleselan is a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia and a hematologic cancer. As a life-cycle extension to uproleselan, it has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is designed to inhibit both E-selectin and CXCR4. The Galectin-3 is a carbohydrate-binding protein. Rivipansel is a glycomimetic drug that acts as a pan-selectin antagonist that binds to all three members of the selectin family, E-, P- and L-selectin, for the treatment of vaso-occlusive crisis.

Webull offers kinds of GlycoMimetics Inc stock information, including NASDAQ:GLYC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLYC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GLYC stock methods without spending real money on the virtual paper trading platform.